Correction to: British Journal of Cancer (2019) 120, 183–189; https://doi.org/10.1038/s41416-018-0343-z; published online 11 December 2018
The original version of this article contained an error in Fig. 1a. The number of patients at risk listed in the Veliparib arm of Fig. 1a should have read “65” instead of “35”. The correct figure is below.
a Progression-free survival at final analysis and b overall survival at final analysis. CI confidence interval, PBO placebo + FOLFIRI ± bevacizumab, VEL veliparib + FOLFIRI ± bevacizumab
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gorbunova, V., Beck, J.T., Hofheinz, RD. et al. Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. Br J Cancer 121, 429–430 (2019). https://doi.org/10.1038/s41416-019-0528-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-019-0528-0
